In the phase 2 ATLANTIC trial that investigated the efficacy of the anti-PD-L1 antibody durvalumab in advanced-stage NSCLC, the response rate was 3.6% in patients with a PD-L1 expression of < 25% and 12.2% in those with a PD-L1 expression of > 25% and those with EGFR or ALK mutations [16]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.